Guangji Pharm. Achieves Operating Revenue of 738 Million Yuan and 56.27% Surge Y/Y for 2023 & Q1 2024 Respectively; The VB12 Line in its Holding Subsidiary Guangji Pharmaceutical (Mengzhou) Co., Ltd. Halts Production-EFFAMALL

Home Page / Effamall Information

Guangji Pharm. Achieves Operating Revenue of 738 Million Yuan and 56.27% Surge Y/Y for 2023 & Q1 2024 Respectively; The VB12 Line in its Holding Subsidiary Guangji Pharmaceutical (Mengzhou) Co., Ltd. Halts Production

Published on： Invalid date Categories： Author：

<Prev

Next>

Tag：

Article links： https://www.effamall.com/article/1784430361908412416.html

Related Recommendations